Evolution of the efficacy and safety of Dexamethasone administration in COVID-19
Phase 2
- Conditions
- COVID-19 pneumonia.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20151227025726N17
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Patients between 18 and 65 years old
Laboratory COVID-19 confirmed with RT-PCR
Mild to moderately ill patients
Patients with PaO2/FiO2 between 100-300
Signed the consent form
Exclusion Criteria
Acute or chronic renal impairment (Creatinin rise more than 3 units in the last 48 hours and/or GFR less than 30 mL/min)
Chronic liver disease (Rise in LFTs more than 5 times and/or 3 times rise in LFTs in symptomatic patients and/or Child pugh C,D)
Allergy to corticosteriods while being injected with extravasation and signs of anaphylactic shock.
Patients with hyperglycemia
Pregnancy and lactation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eed for invasive mechanical ventilation. Timepoint: Daily. Method of measurement: Medical record.;Death. Timepoint: At the end of the study. Method of measurement: Medical record.
- Secondary Outcome Measures
Name Time Method Weaning from oxygen support. Timepoint: Daily. Method of measurement: Medical record.;Length of hospital stay. Timepoint: At the end of the study. Method of measurement: Medical record.;Lung radiology changes. Timepoint: At admission time and seven and 14 days later. Method of measurement: At admission time and seven and 14 days later.